The Motley Fool··James HalleyRelay Therapeutics Advances Rare Disease Pipeline With Encouraging Vascular Anomaly Trial Data
Relay Therapeutics reports 60% response rate in phase 2 vascular anomaly trial, backed by $642M cash and planned 2027 phase 3 launch.
PFERLAYcash positionclinical-stage biotech